Mitsubishi Tanabe Acquires Vaccine Development Partner Medicago
This article was originally published in PharmAsia News
Executive Summary
The Japanese firm hopes to broaden its domestic vaccine presence globally and gains virus-like particle technology in the deal to widen its therapeutic targets.